- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Glucotrack CEO explains tech behind long-term CBGM implant | 1 | MassDevice | ||
| 15.05. | Glucotrack reports Q1 results | 1 | Seeking Alpha | ||
| 14.05. | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 487 | GlobeNewswire (Europe) | Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring... ► Artikel lesen | |
| 14.05. | Glucotrack, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.05. | Glucotrack, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 07.05. | Glucotrack submits long-term implantable CBGM for FDA IDE | - | MassDevice | ||
| 07.05. | Glucotrack beantragt FDA-Zulassung für implantierbaren Blutzuckermonitor | 4 | Investing.com Deutsch | ||
| 07.05. | Glucotrack, Inc.: Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology | 164 | GlobeNewswire (Europe) | RUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
| 30.04. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | Glucotrack, Inc.: Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology | 2 | GlobeNewswire (USA) | ||
| 21.04. | Glucotrack veröffentlicht Peer-Review-Studie zur Langzeitstabilität seines Glukosesensors | 3 | Investing.com Deutsch | ||
| 14.04. | Glucotrack wandelt Schuldschein über 600.000 US-Dollar in Aktien um | 4 | Investing.com Deutsch | ||
| 14.04. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.03. | GlucoTrack, Inc.: Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | 389 | GlobeNewswire (Europe) | Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents... ► Artikel lesen | |
| 30.03. | Glucotrack GAAP EPS of -$31.22 | 1 | Seeking Alpha | ||
| 30.03. | Glucotrack, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | GlucoTrack Shares Surge 34% On FDA Submission Progress For Implantable Glucose Monitor | 2 | RTTNews | ||
| 27.03. | GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech | 1 | Benzinga.com | ||
| 27.03. | Glucotrack to submit continuous blood glucose monitor for FDA IDE in early Q2 | 1 | MassDevice | ||
| 27.03. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,270 | -0,91 % | EQS-News: Eckert & Ziegler SE: Hauptversammlung der Eckert & Ziegler SE beschließt deutlich höhere Dividende | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Hauptversammlung/Dividende
Hauptversammlung der Eckert & Ziegler SE beschließt deutlich höhere Dividende
24.06.2026 / 15:44... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,090 | +5,90 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB: Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden | EQS-News: SYNLAB
/ Schlagwort(e): Sonstiges
Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden
31.03.2026... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,013 | -5,71 % | NuGen Medical Devices Inc.: NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection Performance | Toronto, Ontario--(Newsfile Corp. - May 28, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle free drug delivery, today announced the filing of a new... ► Artikel lesen | |
| HEALWELL AI | 0,476 | -2,66 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| UNIDOC HEALTH | 0,057 | -9,46 % | UniDoc Health Corp.: UniDoc Connect Surpasses One Million Patient Visits | Company Records 250,000 Patient Visits in First Six Months Since AMD Purchase, Then Triples to 750,000 in the Following Six Months VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / UniDoc Health Corp.... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results | Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025Net... ► Artikel lesen | |
| CO-DIAGNOSTICS | 2,980 | 0,00 % | Co-Diagnostics Reports First Quarter 2026 Financial Results | Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion
Executing Clinical Strategy with Upper Respiratory Submission Preparation... ► Artikel lesen | |
| MEDIVOLVE | - | - | Medivolve Inc (2): OSC cites Bharti, Said for disclosure failures | ||
| QUIDELORTHO | 12,480 | +3,14 % | QuidelOrtho Corporation: QuidelOrtho Appoints Micah Young as Chief Financial Officer | Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq:... ► Artikel lesen | |
| VERU | 3,120 | 0,00 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| QUEST DIAGNOSTICS | 184,15 | -0,05 % | Quest Diagnostics' Haystack MRD Test Wins New York State Approval For Solid Tumor Monitoring | WASHINGTON (dpa-AFX) - Wednesday, Quest Diagnostics Inc. (DGX) announced that the New York State Department of Health's Clinical Laboratory Evaluation Program has approved the company's Haystack... ► Artikel lesen | |
| LIFEWARD | 7,060 | -1,94 % | Lifeward Ltd.: Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform | Veteran physician- medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience- mobility technologies, and metabolic disease... ► Artikel lesen | |
| SENSEONICS | 5,200 | +2,97 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.